WO2000069909A9 - Isolation and characterization of epidermal growth factor related protein - Google Patents

Isolation and characterization of epidermal growth factor related protein

Info

Publication number
WO2000069909A9
WO2000069909A9 PCT/US2000/012884 US0012884W WO0069909A9 WO 2000069909 A9 WO2000069909 A9 WO 2000069909A9 US 0012884 W US0012884 W US 0012884W WO 0069909 A9 WO0069909 A9 WO 0069909A9
Authority
WO
WIPO (PCT)
Prior art keywords
errp
cdna
egfr
cells
hct
Prior art date
Application number
PCT/US2000/012884
Other languages
French (fr)
Other versions
WO2000069909A1 (en
Inventor
Adhip Majumdar
Original Assignee
Us Of America Through The Dept
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Of America Through The Dept filed Critical Us Of America Through The Dept
Priority to AU50032/00A priority Critical patent/AU5003200A/en
Publication of WO2000069909A1 publication Critical patent/WO2000069909A1/en
Publication of WO2000069909A9 publication Critical patent/WO2000069909A9/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Definitions

  • This invention relates to the epidermal growth factor related proteins, polynucleotides encoding these proteins and methods for using these proteins.
  • the cellular machinery involved in mitogenesis is complex, and not yet fully understood.
  • receptors present on the cell surface bind growth factors, resulting in an activated receptor.
  • tyrosine kinase receptors TLRs
  • the activated receptors phosphorylate intracellular substrates. These phosphorylated substrates are responsible for a series of events that leads to cell division. This process is generally referred to as "mitogenic signal transduction.
  • the molecular machinery involved in this process is considered to be the "mitogenic signaling pathway.”
  • TKRs cell surface tyrosine kinase receptors
  • PLC-7 phospholipase C
  • GAP GTPase activating protein
  • EGF Epidermal growth factor
  • EGFR Epidermal growth factor receptor
  • Errors which occur in the mitogenic signaling pathway are implicated in malignant transformation and cancer. It is believed that in at least some malignancies, interference with such abnormal mitogenic signal transduction could cause the cells to revert to normal phenotype.
  • reagents useful in identifying molecular components of the mitogenic signaling pathway find utility as tumor markers for therapeutic, diagnostic, and prognostic purposes. Furthermore, identification of how such components differ from normal components in malignant tissue would be of significant value in understanding and treating such malignancies.
  • EGFR a 170 kDa transmembrane glycoprotein protein with intrinsic tyrosine kinase activity, which binds EGF family of peptides, plays an important role in controlling cell proliferation and differentiation as was shown by Ullrich et al. supra.
  • the EGFR possesses three functional domains that include extracellular, transmembrane and cytoplasmic. Ligand binding to the extacellular domain of EGFR leads to dimerization and activation of the receptor's intrinsic tyrosine kinase, located in the cytoplasmic domain, triggering a complex array of enzymatic and biological events leading to cell proliferation and differentiation.
  • EGFR Overexpression of EGFR has been associated with many malignancies, including cancers of the stomach and colon. Evidence is accumulating which show that malignant as well as certain normal cells also produce other form(s) of EGFR.
  • A431 human epidermoid carcinoma cells have been shown to produce a truncated EGFR that encodes a 2.8 kb mRNA transcript and is thought to be the result of gene rearrangement in chromosome 7.
  • the normal rat liver produces a 2.7 kb mRNA transcript whose 5 ⁇ but not 3', sequences show 100% homology with the external domain of the full-length rat EGFR .
  • the present invention is directed toward a polynucleotide sequence, proteins transcribed from the nucleotide sequence, methods for the use of epidermal growth factor receptor related protein (ERRP) as well as probes for the detection of m-RNA, DNA and cDNA of the described nucleotide sequence and monoclonal antibodies directed toward ERRP.
  • ERRP epidermal growth factor receptor related protein
  • a cDNA fragment clone of 1583 base pairs with 90-95% sequence homology to mouse epidermal growth factor receptor (EGFR) and a truncated rat EGFR was isolated.
  • the full length cDNA revealed 1958 base pairs that contained 227 base pairs of 5' untranslated region and an open reading frame encoding 479 amino acids followed by 290 base pairs of an untranslated region.
  • the full length cDNA showed an 84% and 91 % homology, respectively, to a rat truncated EGFR and the mouse EGFR.
  • ERRP EGF-Receptor Related Protein
  • ERRP cDNA hybridized strongly to a mRNA transcript of about 1.8Kb. Maximal expression was noted in the small intestine, followed by colon, liver gastric mucosa and other tissue.
  • the ERRP cDNA represents a new member of the EGFR gene family and the protein product plays a key role in modulating the function of EGFR.
  • Fig. 1 Schematic representation of ERRP cDNA showing its homology to a rat truncated EGF-R (T-EGER).
  • Fig. 2 Northern-blot analysis showing the mRNA transcript size of
  • ERRP in different tissues in rats. Each lane contains l ⁇ g poly A -I- RNA. The membrane was also probed with GAPDH. Changes in relative concentration of
  • ERRP mRNA expressed as ratio of ERRP to GAPDH, are shown at the bottom of the figure.
  • Fig. 3 RT-PCR reaction showing changes in mRNA levels of ERRP and GAPDH in the control (vector-transfected) and ERRP cDNA transfected (clones 1 and 2) HCT-116 cells. RT-PCR was performed with primers for
  • Lanes 1, 2 and 3 represent clones 2, 1 and controls respectively.
  • Lanes 4, 5 and 6 represent clones 2, 1 and control.
  • Lanes 7, 8 and 9 represent clones 2, 1 and controls. Lane L represents DNA ladder.
  • Fig. 4 Effect of ERRP cDNA transfection on proliferation of HCT-
  • the control (vector-transfected) and ERRP cDNA transfected cells were maintained in DMEM/10% FBS. Each value represents mean ⁇ SEM for 6 observations.
  • Fig. 5 Effects of increasing concentrations of TGF- ⁇ on proliferation of ERRP cDNA or vector-transfected CHT-116 cells. Values represent mean
  • Fig. 6 Clonogenic assay in soft agar showing changes in proliferation of HCT-116 following transfection with either ERRP cDNA (clones 1 and 2) or the vector only (controls).
  • ERRP cDNA clones 1 and 2
  • a vector only controls.
  • One milliliter containing 100 cells were sandwiched between 1.8% and 0.3% agarose in DMEM/10% FBS. Plates were incubated at 37°C for 14 days. Values represent mean +SEM of 6 observations.
  • Fig. 7 Illustration of the changes in EGF-R tyrosine kinase (Tyr-K) actively in HCT-116 following transfection with ERRP cDNA (clones 1 and 2). Control cells were transfected with the vector.
  • Fig. 8 Illustration of the effect of ERRP-fiision protein on EGF-R
  • Fig. 9 Comparison of the effects of ERRP-fiision protein of proliferation of HC-116 cells. Cells were exposed to a concentration of 3, 70 and 300 ng/ml of ERRP fusion protein for 48 hours.
  • Fig. 10 Tumor growth in SCID mouse xenografts showing the difference in the rate of growth of tumors formed by HCT-116 cells, transfected with ERRP cDNA (clones 1 and 2) or the vector only (control).
  • Fig. 11 Autoradiograph showing changes in the activation of EGF-R tyrosine kinase in HCT-116 cells following transfaction with ERRP cDNA
  • Fig. 12 Effect of serum starvation (0.1 % FBS) on proliferation of ERRP-overexpressed (clones 1 and 2) and vector transfected (control) HCT-116 cells. Detailed Description of the Invention
  • the full-length cDNA thus obtained consisted of 1958 bp which contained 227 bp 5' untranslated region and an open reading frame (ORF) that coded for 479 amino acids which showed a 84% and 91 % homology, respectively, with the rat truncated EGFR and the external domain of the mouse EGFR. It also possessed a little over 80% homology with the external domain of the human EGFR.
  • ORF open reading frame
  • the full-length cDNA was isolated and consists of 1958 base pairs (bp) that included 227 bp 5' untranslated region (UTR) and a putative open reading frame (ORF) of 1437 nucleotides encoding 479 amino acids, and a 290 nucleotide 3' UTR as is shown in Sequence 1.
  • bp bp 5' untranslated region
  • ORF putative open reading frame
  • ERRP cDNA hybridized strongly to a mRNA transcript of about 1.8 kb with maximal expression noted in the small intestine, followed by colon, liver, gastric mucosa and other tissues. No hybridization of ERRP cDNA to 1.8 kb mRNA transcript was observed in testes, brain and heart. In addition to the 1.8 kb mRNA transcript, ERRP cDNA also reacted strongly with 2.8 kb transcript in the liver, and with 0.6, 2.8 and 5.0 kb mRNAs in certain tissues, most notably in the colon. The transcript size 5.0 kb may represent EGFR. However, no expression of ERRP mRNA was observed in the heart as is shown in Fig. 2.
  • cDNA for ERRP was stably transfected in HCT-116 cells, a colon cancer cell line.
  • RNA extracted from cells grown from these clones were subsequently subjected to RT-PCR analysis with primers generated from 1.6 kb fragment of the full-length 1.8 kb ERRP.
  • RT-PCR analysis revealed ERRP mRNA in clones #1 and #2 with minimal to no-detectable levels in the other two clones as is shown in Fig. 3.
  • ERRP expression was higher in clone #1 than clone #2.
  • No ERRP mRNA was detected in control cells (transfected with the vector alone). In contrast, no apparent difference in GAPDH mRNA levels were found among the different clones.
  • TGF- ⁇ -induced proliferation of ERRP transfected and control HCT-116 cells was examined.
  • 48 h serum-starved (0.1 % FBS) cells from clones 1 and 2 as well as those from the vector-transfected clone were maintained for 24 h in the absence (basal) or presence of increasing concentration of TGF- ⁇ (10 "n to 10 '9 M).
  • transfection of ERRP in HCT-116 cells was examined in soft agar over a period of 14 days.
  • transfection of ERRP in HCT-116 cells markedly decreased their ability to grow in soft agar.
  • Number of colonies formed by clones 1 and 2 were 65% and 40% lower, respectively, compared to the control clone. Size of the colonies formed by clone 1 or 2 was also found to be considerably smaller than those formed by the vector- transfected control clone.
  • Serum starvation also resulted in a marked 50-70% inhibition in proliferation of ERRP-transfected HCT-116 cells (clones 1 and 2) compared to the vector-transfected control cells as seen in Fig. 12.
  • the role of ERRP in regulating EGF-R Tyr-K activity was determined by raising an ERRP fusion protein in E. coli. Purified ERRP-fiision protein was bound to its carrier MBP (molecular binding protein, then utilized to study its effects on EGF-R Tyr-K activity in HCT-116 cells, as seen in Fig. 8.
  • HCT-116 cells were exposed to 5 ⁇ g of MBP-bound ERRP for 5 minutes at 37 °C a marked reduction (80-90%) in EGF-R Tyr-K activity was observed when compared to HCT-116 cells exposed to either MBP alone or to control cells.
  • the antiproliferation effect of ERRP-fiision protein was determined by exposing HCT-116 cells to ERRP-fiision protein for 48 hours. As is seen in Fig. 9, exposure of HCT-116 cells to the ERRP fusion protein for 48 hours reduced proliferation by 25-30% compared to control cells.
  • mice were injected with either 5x10° HCT-116 cells (clone 1 or 2) per flank or 5xl0 6 HCT-116 cells (control, transfected with vector) per flank. Tumor growth was monitored and when the tumor(s) attained the size of approximately 1800 mg, the mice were killed. It was observed that in mice injected with control cells, the tumor(s) attained the required weight on the 24 th day after injection, whereas with clone 1 or 2, it took 14-16 days longer for tumor(s) to grow to that size as is seen in Fig. 10. Tumor growth was slowest for clone 1 transfected cells as was colony formation in soft agar.
  • the ERRP was isolated and characterized and the fusion protein made in the following example.
  • RNA-STAT solution Tel-Test, Friendswood, TX
  • poly A + was isolated from total RNA by oligo(dT) cellulose chromatography according to the instructions provided by GIBCO-BRL (Gaithersburg, MD).
  • cDNA expression library and screening Poly A + RNA, isolated from mucosal scrapings from the gastro-duodenal region of the gastrointestinal tract was utilized for this purpose.
  • An unamplified cDNA expression library was constructed using the EcoRI cloning sites of the ⁇ gll vector system in Y1090r- strain according to the conditions recommended by Stratagene (La Jolla, CA).
  • the ligated vector-insert was packaged using Giga- Pack bacterial extracts supplied by Stratagene.
  • the library thus constructed contained 3 x 10 6 pfu (plaque forming units) per ml. Non-recombinant phage associated with the library was about 4%.
  • the reason for constructing an unamplified mucosal library was to minimize the analysis of identical positive clones.
  • the mixture was incubated at 41 °C for 2 h and the product was subsequently used for amplification of 3 '-end of 1.6 kb fragment of ERRP.
  • the reaction mixture in 50 ⁇ l contained: 1 ⁇ l of first strand cDNA, 3'-end primer [5 * -CGCACTCCTCCTCTAGACCCAC-3'] and (dT) 17-adaptor [25 pmol each], 10% dimethylsulfoxide, 1.5 mM of each dNTP.
  • the mixture was heat denatured for 5 min at 95 °C, annealed for 2 min at 53° C in the presence of 2.5 U of Taq DNA polymerase followed by extension for 40 min at 75 °C.
  • the PCR reaction for amplification was carried out for 40 cycles using a step program (denaturation at 94°C for 40 sec; annealing at 53 °C for 2 min and extension at 72°C for 3 min) followed by a 15 min final extension at 72 °C.
  • PCR products from above were directly ligated into pCRII vector (TA cloning kit, Invitogen Corp.), followed by transformation of electro- competent E. Coli DH5 ⁇ cells with one tenth (l/10 ,h ) of the ligation DNA. Approximately 10,000 independent bacterial colonies were screened by colony hybridization mrthodology using PCR amplified 3' end of ERRP cDNA (from positions 1444 to 1578) as probe. Several independent colonies were identified, followed by the secondary screening in order to obtain purified plasmids.
  • pCRII vector TA cloning kit, Invitogen Corp.
  • UV cross-linker Strategene, La Jolla, CA
  • Hybridization with 32 P-labeled RNA probe of 1.5 kb cDNA under study was performed for 18 h at 50° C in the same solution.
  • the plasmid pBK containing 1.6 kb cDNA was linearized by digesting with Pstl.
  • the antisense RNA probe was then synthesized using 1 ⁇ g of linearized plasmid with T3 RNA polymerase with the use of a commercial kit (StripAble RNA, Ambion, Austin, TX). Glyceraldehyde-3- phosphate dehydrogenase (GAPDH) was used as an internal control.
  • GAPDH RNA probe was prepared by transcribing 1 ⁇ g of pTRl-GAPDH (rat; Ambion) with T3 RNA polymerase. The probes were labeled with [( ⁇ - 32 P]UTP according to the manufacturer's instructions.
  • HCT-116 cells maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/ml streptomycin-penicillin and 0.25 ⁇ g/ml amphotericin B, were transfected with either 1.6 kb portion of the 1.8 kb full-length ERRP cDNA or the vector alone (control) by lipofectin according to the manufacturer's instruction (GIBCO-
  • Oligo (dT)16 and 2.5 MuLV reverse transcriptase were incubated at room temperature for 10 min followed by incubations at 42°C for 30 min, 95 °C for 5 min and finally 5°C for 5 min.
  • First strand cDNA thus obtained was used for PCR analysis utilizing Amplitaq DNA polymerase (Perkin Elmer) and 0.15 ⁇ M of upstream primer [5'-
  • CGCACTCCTCCTCTAGACCCAC-3' (taken from ERRP sequence) and 0.15 ⁇ M downstream primer [5 ⁇ TTAACCCTCACTAAAGGGA3'] taken from pcDNA 3.1(+) vector, and/or GAPDH upstream [5'- ACCACAGTCCATGCCATCAC-3'] and downstream primers [5- TCCACCACCCTGTTGCTGTA-3 '] .
  • the PCR reaction for amplification was carried out for 35 cycles using a step program (denaturation at 95 °C for 1 min; annealing at 63 °C for 1 min and extension at 72 °C for 1 min followed by a 15 * min final extension at 72 °C.
  • Tyrosine kinase activity of EGFR The enzyme activity was determined in lysed cells according to our standard protocol. Briefly, plated cells were lysed in lysis buffer [50 mM tris-HC], pH 7.4, 100 mM NaCl, 2.5 mM EDTA, 1 % Triton X-100, 1 % Nonidet P-40, 2.5 nM Na 3 VO 4 , 25 ⁇ g/ml aprotinen, 25 ⁇ g/ml leupeptin and 50 ⁇ g/ml soybean trypsin inhibitor] using a Dounce homogenizer The homogenate was stirred in a mechanical rotator for
  • the immune complexes were precipitated with Sepharose bound protein-G, washed several times with kinase buffer (25 mM HEPES, pH 7.5, 5 mM mnCl 2 , 2.5 mM MgCl 2 , 0.5 mM, ditheothreitol, 0.5 mM Na 3 VO 4 , 10 mM p-nitrophenol phosphate, 5 mM ⁇ -glyverol phosphate).
  • the immunoprecipitates were resuspending in 30 ⁇ l kinase reaction buffer [HEPES, pH 7.5, 10 mM MnCl 2 , 2.5 mM MgCl 2 , 0.1 M Nacl

Abstract

A cDNA fragment clone of 1583 base pairs with 90-95 % sequence homology to the mouse EGFR and a truncated rat EGFR was isolated. The isolated cDNA lacked the 'termination' codon, rapid amplification of cDNA ends (RACE) was applied to obtain the 3'-terminal end. The full-length cDNA revealed 1753 base pairs that contained 227 base pairs of 5' untranslated region and an open reading frame encoding 473 amino acids which showed an 84 % and 91 % homology, respectively, to a rat truncated EGFR and the mouse EGFR. We refer to the product of the newly isolated cDNA as ERRP (EGF-Receptor Related Protein). In Northern-blot analysis with poly A+ RNA from different rat tissues, ERRP cDNA hybridized strongly to a mRNA transcript of about 1.8 kb. Maximal expression was noted in the small intestine, followed by colon, liver, gastric mucosa and other tissues. Transfection of ERRP cDNA in HCT-116 cells, a colon cancer cell line, markedly inhibits proliferation in monolayer and in soft agar and attenuates EGF-R tyrosine kinase activity. Transfection of ERRP in HCT-116 also delays tumor growth in SCID mice injected with these cells compared to the vector-transfected control cells. On the other hand, proliferation of the vector-transfected control, but not ERRP transfected HCT cells could be stimulated by TGF-α (10-10M and 10-9M). The ERRP cDNA represents a new member of the EGFR gene family, and its protein product plays a key role in modulating the function of EGFR.

Description

ISOLATION AND CHARACTERIZATION OF EPIDERMAL GROWTH FACTOR RELATED PROTEIN
This work has been supported by the Department of Veterans Affairs. The United States Government retains certain rights in this invention.
Field of the Invention
This invention relates to the epidermal growth factor related proteins, polynucleotides encoding these proteins and methods for using these proteins. The cellular machinery involved in mitogenesis is complex, and not yet fully understood. In general, receptors present on the cell surface bind growth factors, resulting in an activated receptor. In particular, tyrosine kinase receptors (TKRs) are endowed with intrinsic tyrosine kinase activity. The activated receptors, in turn, phosphorylate intracellular substrates. These phosphorylated substrates are responsible for a series of events that leads to cell division. This process is generally referred to as "mitogenic signal transduction. " The molecular machinery involved in this process is considered to be the "mitogenic signaling pathway."
Growth factors and hormones exert pleiotropic effects on cellular functions, including mitogenic stimulation and modulation of differentiation and metabolism (Ullrich, et al. Cell 61:203-212 (1990); Aaronson, S.A. Science 254: 1146-1153 (1991)). In many cases, these actions are mediated by the interaction of growth factors with cell surface tyrosine kinase receptors (TKRs), which results in enhanced receptor catalytic activity and tyrosine phosphorylation of intracellular substrates (Ullrich, et al., supra, Aaronson, supra). Knowledge of the nature of these second messenger systems is still scanty, although some molecules which associate and/or are tyrosine phosphorylated by TKRs have been identified. These include the γ isozyme of phospholipase C (PLC-7) (Margolis, et al. Call 57: 1101-1107 (1989), Meinsenhelder, et al. Cell 57: 1109-1122 (1989) and Wahl, et al. Mol. Cell. Biol. 9: 2934-2943 (1989)); the p21ras GTPase activating protein (GAP) (Molloy, et al. Nature 342: 711-714 (1989), Kaplan, et al. Cell 61:125-133
(1990), and Kazlauskas, et al. Science 247: 1578-1581 (1990)); the raf serine- threonine kinase (Morrison, et al. Proc. Natl. Acad. Sci. USA 85: 8855-8859 (1988), and Morrison, et al. Cell 58: 649-657 (1989)); the p85 subunit of the phosphatidylinositol 3-kinase (Ptdlns-3K); (Coughlin, et al. Science 243: 1191- 1194 (1989) Kazlauskas, et al. Cell 58: 1121-1133 (1989), Varticovski, et al.
Nature 342: 699-702 (1989), Ruderman, et al. Proc. Natl. Acad. Sci. USA 87: 1411-1415 (1990), Escobedo, et al. Cell 65: 75-82 (1991), Skolnik, et al. Cell 65: 83-90 (1991), Otsu, et al. Cell 65: 91-104 (1991)) and some cytoplasmic tyrosine kinases (Gould, et al. Mol. Cell. Biol. 8: 3345-3356 (1988); Kypta, et al. Cell 62: 481-492 (1990)). These signaling molecules are thought to mediate at least in part the mitogenic effects of TKRs (Ullrich, et al. supra; Aaronson, supra).
However, the Epidermal growth factor (EGF) receptor (EGFR) does not appear to efficiently interact with known second messenger systems (Fazioli, et al. Mol. Cell. Biol. 11: 2040-2048 (1991); Segatto, et al. Mol. Cell. Biol. 11:
3191-3202 (1991)). Thus, there is need to ascertain the mechanism by which the EGFR functions in mitogenesis, and a particular need to identify and characterize the substrate (if any) of the EGFR.
Errors which occur in the mitogenic signaling pathway, such as alterations in one or more elements of that pathway, are implicated in malignant transformation and cancer. It is believed that in at least some malignancies, interference with such abnormal mitogenic signal transduction could cause the cells to revert to normal phenotype.
In addition, reagents useful in identifying molecular components of the mitogenic signaling pathway find utility as tumor markers for therapeutic, diagnostic, and prognostic purposes. Furthermore, identification of how such components differ from normal components in malignant tissue would be of significant value in understanding and treating such malignancies.
EGFR, a 170 kDa transmembrane glycoprotein protein with intrinsic tyrosine kinase activity, which binds EGF family of peptides, plays an important role in controlling cell proliferation and differentiation as was shown by Ullrich et al. supra. The EGFR possesses three functional domains that include extracellular, transmembrane and cytoplasmic. Ligand binding to the extacellular domain of EGFR leads to dimerization and activation of the receptor's intrinsic tyrosine kinase, located in the cytoplasmic domain, triggering a complex array of enzymatic and biological events leading to cell proliferation and differentiation.
Overexpression of EGFR has been associated with many malignancies, including cancers of the stomach and colon. Evidence is accumulating which show that malignant as well as certain normal cells also produce other form(s) of EGFR. For example, A431 human epidermoid carcinoma cells have been shown to produce a truncated EGFR that encodes a 2.8 kb mRNA transcript and is thought to be the result of gene rearrangement in chromosome 7. Likewise, the normal rat liver produces a 2.7 kb mRNA transcript whose 5\ but not 3', sequences show 100% homology with the external domain of the full-length rat EGFR . This and other relevant observations suggest that this truncated form of EGFR mRNA, whose protein product is also secreted from the cell, is generated from alternative splicing of the primary EGFR transcript. A shorter 1.8 kb alternative transcript from the human EGFR, which also produces a secreted product, has been isolated from a human placental cDNA library (Reiter J.L., Maihle, N.J. Nucleic Acid Research 24:4050-4056, 1996).
Summary of the Invention
The present invention is directed toward a polynucleotide sequence, proteins transcribed from the nucleotide sequence, methods for the use of epidermal growth factor receptor related protein (ERRP) as well as probes for the detection of m-RNA, DNA and cDNA of the described nucleotide sequence and monoclonal antibodies directed toward ERRP.
In particular, a cDNA fragment clone of 1583 base pairs with 90-95% sequence homology to mouse epidermal growth factor receptor (EGFR) and a truncated rat EGFR was isolated. The full length cDNA revealed 1958 base pairs that contained 227 base pairs of 5' untranslated region and an open reading frame encoding 479 amino acids followed by 290 base pairs of an untranslated region. The full length cDNA showed an 84% and 91 % homology, respectively, to a rat truncated EGFR and the mouse EGFR. The product of the newly isolated DNA is referred to as ERRP (EGF-Receptor Related Protein). In a Northern-blot analysis with poly A+ RNA from different rat tissues, ERRP cDNA hybridized strongly to a mRNA transcript of about 1.8Kb. Maximal expression was noted in the small intestine, followed by colon, liver gastric mucosa and other tissue. Transfection of ERRP cDNA in HCT-116 cells, a colon cancer cell line, markedly inhibited (40-60%) proliferation in monolayer and soft agar and also attenuated EGFR tyrosine kinase activity compared to vector-transfected control cells. Proliferation of the vector-transfected control, but not ERRP transfected HCT cells could be stimulated by TGF-c (10~10μ and 10"9μ). The over expression of ERRP in HCT-116 cell delayed tumor growth in SCID mice xenografts. The ERRP cDNA represents a new member of the EGFR gene family and the protein product plays a key role in modulating the function of EGFR.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1: Schematic representation of ERRP cDNA showing its homology to a rat truncated EGF-R (T-EGER).
Fig. 2: Northern-blot analysis showing the mRNA transcript size of
ERRP in different tissues in rats. Each lane contains lμg poly A -I- RNA. The membrane was also probed with GAPDH. Changes in relative concentration of
ERRP mRNA, expressed as ratio of ERRP to GAPDH, are shown at the bottom of the figure.
Fig. 3: RT-PCR reaction showing changes in mRNA levels of ERRP and GAPDH in the control (vector-transfected) and ERRP cDNA transfected (clones 1 and 2) HCT-116 cells. RT-PCR was performed with primers for
ERRP and GAPDH simultaneously (lanes 1-3) or with primers for ERRP (lanes
4-6) or GAPDH (lanes 7-9). Lanes 1, 2 and 3 represent clones 2, 1 and controls respectively. Lanes 4, 5 and 6 represent clones 2, 1 and control.
Lanes 7, 8 and 9 represent clones 2, 1 and controls. Lane L represents DNA ladder. Fig. 4: Effect of ERRP cDNA transfection on proliferation of HCT-
116 cells. The control (vector-transfected) and ERRP cDNA transfected cells were maintained in DMEM/10% FBS. Each value represents mean ±SEM for 6 observations.
Fig. 5: Effects of increasing concentrations of TGF-α on proliferation of ERRP cDNA or vector-transfected CHT-116 cells. Values represent mean
±SEM for 6.
Fig. 6: Clonogenic assay in soft agar showing changes in proliferation of HCT-116 following transfection with either ERRP cDNA (clones 1 and 2) or the vector only (controls). One milliliter containing 100 cells were sandwiched between 1.8% and 0.3% agarose in DMEM/10% FBS. Plates were incubated at 37°C for 14 days. Values represent mean +SEM of 6 observations.
Fig. 7: Illustration of the changes in EGF-R tyrosine kinase (Tyr-K) actively in HCT-116 following transfection with ERRP cDNA (clones 1 and 2). Control cells were transfected with the vector. Fig. 8: Illustration of the effect of ERRP-fiision protein on EGF-R
Tyr-K activity in HCT-116 cells. Cells were exposed to either 5μg of ERRP fusion protein bound to MBR or MBP alone for 5 minutes at 37 °C.
Fig. 9: Comparison of the effects of ERRP-fiision protein of proliferation of HC-116 cells. Cells were exposed to a concentration of 3, 70 and 300 ng/ml of ERRP fusion protein for 48 hours.
Fig. 10: Tumor growth in SCID mouse xenografts showing the difference in the rate of growth of tumors formed by HCT-116 cells, transfected with ERRP cDNA (clones 1 and 2) or the vector only (control).
Fig. 11: Autoradiograph showing changes in the activation of EGF-R tyrosine kinase in HCT-116 cells following transfaction with ERRP cDNA
(clones 1 and 2, marked as Al and A2) or the vector only (control) as determined by the extent of phosphophylation of acid-denatured enolase. The cell maintained in DMEM cell medium containing 0.1 % FBS.
Fig. 12: Effect of serum starvation (0.1 % FBS) on proliferation of ERRP-overexpressed (clones 1 and 2) and vector transfected (control) HCT-116 cells. Detailed Description of the Invention
It has been demonstrated that stimulation of gastric mucosal proliferative activity, whether the result of aging, injury or the administration of gastrin, bombesin or EGF to young adult rats, is associated with a rise in tyrosine phosphorylation of a membrane protein with a molecular mass of 55 kDa. A similar phenomenon has also been observed in the colonic mucosa of rats after administration of either gastrin or the colonic carcinogen azoxymethane. These and other relevant observations led us to suggest that the 55 kDa phosphotyrosine mucosal membrane protein, which we have referred to as pp55, may play a role in modulating gastrointestinal mucosal cell proliferation. In order to characterize pp55 and to study its functional properties, polyclonal antibodies raised against this protein were used to screen a cDNA expression of a library generated from rat gastro-duodenal mucosal mRNA. A computer search of the nucleotide sequences of one of the candidate cDNA clones showed a significant homology with the extracellular domain of the mouse EGFR (epidermal growth factor receptor) and a rat truncated EGFR.
The latter also possesses considerable homology with the extracellular domain of EGFER (10). We refer to the product of this newly isolated cDNA as ERRP (EGRR Related Peptide).
During the course of screening the cDNA expression library with pp55 antibodies, we isolated a cDNA fragment clone of 1583 base pairs (bp) which showed a 95% sequence homology to the extracellular domain of the mouse EGFR and an 92% homology to a truncated rat EGFR. We refer to the product of this clone as ERRP (EGRR Related Protein). The 1583 bp cDNA fragment possessed the "initiation" ATG codon, but lacked the termination codon. In view of this, RACE was applied to obtain the 3'-terminal end, which resulted in a 375 bp fragment with TGA "termination" codon and the 3' poly A tail. The full-length cDNA thus obtained consisted of 1958 bp which contained 227 bp 5' untranslated region and an open reading frame (ORF) that coded for 479 amino acids which showed a 84% and 91 % homology, respectively, with the rat truncated EGFR and the external domain of the mouse EGFR. It also possessed a little over 80% homology with the external domain of the human EGFR.
However, the first 24 amino acids of the ORF were similar but not identical to those found in the signal peptide of human EGFR. Additionally, a region of the 3' end (referred to as U; nucleotides 1580-1661) encoding 27 amino acids showed no homology with any known sequence in the current data base. The results suggest that ERRP is a new member of the EGFR family.
The full-length cDNA was isolated and consists of 1958 base pairs (bp) that included 227 bp 5' untranslated region (UTR) and a putative open reading frame (ORF) of 1437 nucleotides encoding 479 amino acids, and a 290 nucleotide 3' UTR as is shown in Sequence 1. To determine the expression of ERRP, Northern-blot analysis was performed with poly A -(-RNA from different tissues of the gastrointestinal tract as well as from the liver, brain, heart and testes. Expression of ERRP mRNA varied considerably between the tissues as is shown in Fig. 2. ERRP cDNA hybridized strongly to a mRNA transcript of about 1.8 kb with maximal expression noted in the small intestine, followed by colon, liver, gastric mucosa and other tissues. No hybridization of ERRP cDNA to 1.8 kb mRNA transcript was observed in testes, brain and heart. In addition to the 1.8 kb mRNA transcript, ERRP cDNA also reacted strongly with 2.8 kb transcript in the liver, and with 0.6, 2.8 and 5.0 kb mRNAs in certain tissues, most notably in the colon. The transcript size 5.0 kb may represent EGFR. However, no expression of ERRP mRNA was observed in the heart as is shown in Fig. 2.
To determine putative functional properties of ERRP, cDNA for ERRP was stably transfected in HCT-116 cells, a colon cancer cell line. Four ERRP- positive clones, as evidenced by Northern-blot analysis with poly A + RNA, were selected. For further verification of ERRP transfection, RNA extracted from cells grown from these clones were subsequently subjected to RT-PCR analysis with primers generated from 1.6 kb fragment of the full-length 1.8 kb ERRP. RT-PCR analysis revealed ERRP mRNA in clones #1 and #2 with minimal to no-detectable levels in the other two clones as is shown in Fig. 3. ERRP expression was higher in clone #1 than clone #2. No ERRP mRNA was detected in control cells (transfected with the vector alone). In contrast, no apparent difference in GAPDH mRNA levels were found among the different clones.
To determine putative functional properties of ERRP, the rate of proliferation of ERRP-expressed cells (Clones #1 and 2) was compared with control cells. Results from a 5-day cell culture study revealed that although cells from all three clones grew essentially at the same rate during the first 3 days, the rate of proliferation in ERRP transfected cells decreased markedly during the next two days in culture when compared with controls as is shown in Fig. 4. To demonstrate that the inhibition of HCT-116 cell proliferation by ERRP expression was not due to a "positive effect" of the inserted DHA, we assayed three other distinct ERRP-transfected HCT-116 cell subclones. Each of these subclones exhibited decreased proliferation relative to controls.
TGF-α-induced proliferation of ERRP transfected and control HCT-116 cells was examined. In this investigation, 48 h serum-starved (0.1 % FBS) cells from clones 1 and 2 as well as those from the vector-transfected clone were maintained for 24 h in the absence (basal) or presence of increasing concentration of TGF-α (10"n to 10'9M). Results revealed that whereas TGF-α at a dose of either 10 ° or 10~10M significantly stimulated proliferation in control cells, it had no effect on cells from either clone 1 or clone 2 as is shown in Fig. 5. To determine whether transfection of ERRP in HCT-116 cells will affect the tumorigenic property of this cell line, extent of proliferation of clones 1 and 2 and their control counterpart (vector transfected cells) was examined in soft agar over a period of 14 days. As shown in Fig. 6, transfection of ERRP in HCT-116 cells markedly decreased their ability to grow in soft agar. Number of colonies formed by clones 1 and 2 were 65% and 40% lower, respectively, compared to the control clone. Size of the colonies formed by clone 1 or 2 was also found to be considerably smaller than those formed by the vector- transfected control clone.
To examine the antiproliferative effect of ERRP by the inhibition of the intrinsic tyrosine kinase activity of EGF-R. As is shown in Fig. 7 basal EGF-R R tyrosine kinase activity in ERRP-overexpressed HCT-116 cells (clones 1 and
2) was about 50-60% below the control cells.
Serum starvation also resulted in a marked 50-70% inhibition in proliferation of ERRP-transfected HCT-116 cells (clones 1 and 2) compared to the vector-transfected control cells as seen in Fig. 12. The role of ERRP in regulating EGF-R Tyr-K activity was determined by raising an ERRP fusion protein in E. coli. Purified ERRP-fiision protein was bound to its carrier MBP (molecular binding protein, then utilized to study its effects on EGF-R Tyr-K activity in HCT-116 cells, as seen in Fig. 8. When
HCT-116 cells were exposed to 5μg of MBP-bound ERRP for 5 minutes at 37 °C a marked reduction (80-90%) in EGF-R Tyr-K activity was observed when compared to HCT-116 cells exposed to either MBP alone or to control cells.
The antiproliferation effect of ERRP-fiision protein was determined by exposing HCT-116 cells to ERRP-fiision protein for 48 hours. As is seen in Fig. 9, exposure of HCT-116 cells to the ERRP fusion protein for 48 hours reduced proliferation by 25-30% compared to control cells.
To determine the tumorigenic properties of ERRP, the growth rate of tumors-induced by HCT-116 cells, was examined in SCID mouse xenografts.
Groups of SCID mice were injected with either 5x10° HCT-116 cells (clone 1 or 2) per flank or 5xl06 HCT-116 cells (control, transfected with vector) per flank. Tumor growth was monitored and when the tumor(s) attained the size of approximately 1800 mg, the mice were killed. It was observed that in mice injected with control cells, the tumor(s) attained the required weight on the 24th day after injection, whereas with clone 1 or 2, it took 14-16 days longer for tumor(s) to grow to that size as is seen in Fig. 10. Tumor growth was slowest for clone 1 transfected cells as was colony formation in soft agar.
The ERRP was isolated and characterized and the fusion protein made in the following example.
Methods Isolation of RNA: Total RNA was isolated from different tissues and colon carcinoma cell line HCT-116 utilizing RNA-STAT solution (Tel-Test, Friendswood, TX) according to the manufacturer's instruction. P, poly A + was isolated from total RNA by oligo(dT) cellulose chromatography according to the instructions provided by GIBCO-BRL (Gaithersburg, MD).
Construction ofcDNA expression library and screening: Poly A+ RNA, isolated from mucosal scrapings from the gastro-duodenal region of the gastrointestinal tract was utilized for this purpose. An unamplified cDNA expression library was constructed using the EcoRI cloning sites of the λgll vector system in Y1090r- strain according to the conditions recommended by Stratagene (La Jolla, CA). The ligated vector-insert was packaged using Giga- Pack bacterial extracts supplied by Stratagene. The library thus constructed contained 3 x 106 pfu (plaque forming units) per ml. Non-recombinant phage associated with the library was about 4%. The reason for constructing an unamplified mucosal library was to minimize the analysis of identical positive clones.
Six duplicate IPTG-treated nitrocellulose filters containing the imprint of 50,000 plaques were washed with PBS-0.1 % Tween-20, and left in a blocking buffer (PBS containing 7% nonfat dry milk, 0.5% BSA and 0.1 % Tween-20). Membranes were then washed at room temperature in PBS-0.1 % Tween-20, and subsequently incubated for 2 h at room temperature with pp55 antibodies (1:5000 final dilution) which were pre-adsorbed six times with E. coli lysate protein according to the protocol provided by Strategene. Bound antibody was visualized by the enhanced chemiluminescence (ECL) detection system (Amersham) according to the manufacturer's instruction.
Sequence analysis: DNA from one of the positive plaques (referred to here as ERRP) was isolated and purified. Restriction analysis by EcoRI showed its size to be about 1.6 kb. This was subcloned into EcoRI sites of pBluescript (KS+) vector and subsequently sequenced by the dideoxy chain termination method at the Core Facility of the Center for Molecular Medicine and Genetics, Wayne State University, Detroit. The nucleotide sequence, thus obtained, was compared with known sequences in GenBank using the NCBI BLAST search program. Rapid Amplification ofcDNA Ends (RACE): Since the candidate cDNA under study lacked the termination codon, RACE was utilized to obtain the 3' end in the following manner. Briefly, 1 μg poly A+ from rat small intestinal mucosa was heat denatured at 65 °C for 3 min and reverse transcribed into a single strand cDNA according to the instruction provided by GIBCO-BRL (Gaithersburg, MD) in a 20 μg reaction mixture [50 mM Tris-HCl, pH 8.15, 1 mM each dNTP, 10 mM dithiothreitol, 6 mM MgCl240 mM KCl, 10 U Rnasin (Promega, Madison, WI) 10 U AMV reverse transcriptase (GIBCO-BRL)], 0.5 μg of oligo-dT primer [5 'GACTCGAGTCGACATCGATTTTTTTTTTTTTTTTT-3 '] containing Xhol, Sail and Clal restriction sites. The mixture was incubated at 41 °C for 2 h and the product was subsequently used for amplification of 3 '-end of 1.6 kb fragment of ERRP. The reaction mixture in 50 μl contained: 1 μl of first strand cDNA, 3'-end primer [5*-CGCACTCCTCCTCTAGACCCAC-3'] and (dT) 17-adaptor [25 pmol each], 10% dimethylsulfoxide, 1.5 mM of each dNTP. The mixture was heat denatured for 5 min at 95 °C, annealed for 2 min at 53° C in the presence of 2.5 U of Taq DNA polymerase followed by extension for 40 min at 75 °C. The PCR reaction for amplification was carried out for 40 cycles using a step program (denaturation at 94°C for 40 sec; annealing at 53 °C for 2 min and extension at 72°C for 3 min) followed by a 15 min final extension at 72 °C.
The PCR products from above were directly ligated into pCRII vector (TA cloning kit, Invitogen Corp.), followed by transformation of electro- competent E. Coli DH5α cells with one tenth (l/10,h) of the ligation DNA. Approximately 10,000 independent bacterial colonies were screened by colony hybridization mrthodology using PCR amplified 3' end of ERRP cDNA (from positions 1444 to 1578) as probe. Several independent colonies were identified, followed by the secondary screening in order to obtain purified plasmids.
Northern-blot analysis Aliquots of one microgram of poly A+ RNA isolated from different tissues were electrophoresed in a 1.5% agarose gel containing 2.2 M formaldehyde. After electrophoresis, RNA was transferred to a nylon or nitrocellulose membrane by capillary blotting and subsequently exposed to an UV cross-linker (Strategene, La Jolla, CA) for 30 sec (autocross) and prehybridized in 5 X SSC (1 x SSC, 0.15 M sodium chloride, 0.015 M sodium citrate) containing 2% blocking reagent (Boehringer-Mannheim), 50% formamide and 0.1 % sodium lauroylsarcosine and 0.02% sodium dodecyl sulfate (SDS) for 2 h at 50°C. Hybridization with 32P-labeled RNA probe of 1.5 kb cDNA under study was performed for 18 h at 50° C in the same solution. The plasmid pBK containing 1.6 kb cDNA was linearized by digesting with Pstl. The antisense RNA probe was then synthesized using 1 μg of linearized plasmid with T3 RNA polymerase with the use of a commercial kit (StripAble RNA, Ambion, Austin, TX). Glyceraldehyde-3- phosphate dehydrogenase (GAPDH) was used as an internal control. GAPDH RNA probe was prepared by transcribing 1 μg of pTRl-GAPDH (rat; Ambion) with T3 RNA polymerase. The probes were labeled with [(α-32P]UTP according to the manufacturer's instructions.
Stable transfection of ERRP and Cell Culture: The cDNA 1.6 kb under study, which was subcloned in pBluescript (KS+) vector, was digested with
Pvu II followed by EcoR I. The resultant fragment was inserted into EcoRI/EcoRV cloning sites of the eukaryotic expression vector pcDNA 3.1 (+) containing neomycin-resistant gene [Invitrogen]. The resultant construct and the vector DNA (without cDNA insert) were used to stably transfect a human colon cancer cell line HCT-116.
HCT-116 cells, maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/ml streptomycin-penicillin and 0.25 μg/ml amphotericin B, were transfected with either 1.6 kb portion of the 1.8 kb full-length ERRP cDNA or the vector alone (control) by lipofectin according to the manufacturer's instruction (GIBCO-
BRL) in the presence of neomycin (geneticin G418; GIBCO-BRL). Neomycin- resistant colonies were selected in the presence of 0.6 mg/ml G418. Colonies were picked at random and grown as individual cell lines in the presence of 0.4 mg/ml G418. Each cell line was subjected to RT-PCR analysis according to our standard protocol. Briefly, 3 μg of total RNA was reverse transcribed into first strand cDNA in a 20 μl reaction mixture containing: 2 μl 10 x PCR buffer, 5 mM MgCl2, 1 mM of each dNTP, 20 U RNAse inhibitor, 2.5 μM of
Oligo (dT)16 and 2.5 MuLV reverse transcriptase. The reaction mixture was incubated at room temperature for 10 min followed by incubations at 42°C for 30 min, 95 °C for 5 min and finally 5°C for 5 min. First strand cDNA thus obtained was used for PCR analysis utilizing Amplitaq DNA polymerase (Perkin Elmer) and 0.15 μM of upstream primer [5'-
CGCACTCCTCCTCTAGACCCAC-3'] (taken from ERRP sequence) and 0.15 μM downstream primer [5ΑTTAACCCTCACTAAAGGGA3'] taken from pcDNA 3.1(+) vector, and/or GAPDH upstream [5'- ACCACAGTCCATGCCATCAC-3'] and downstream primers [5- TCCACCACCCTGTTGCTGTA-3 '] . The PCR reaction for amplification was carried out for 35 cycles using a step program (denaturation at 95 °C for 1 min; annealing at 63 °C for 1 min and extension at 72 °C for 1 min followed by a 15 * min final extension at 72 °C. The reaction product was electrophoresed on an 1.5% agarose gel, subsequently stained with ethidium bromide. Tyrosine kinase activity of EGFR: The enzyme activity was determined in lysed cells according to our standard protocol. Briefly, plated cells were lysed in lysis buffer [50 mM tris-HC], pH 7.4, 100 mM NaCl, 2.5 mM EDTA, 1 % Triton X-100, 1 % Nonidet P-40, 2.5 nM Na3VO4, 25 μg/ml aprotinen, 25 μg/ml leupeptin and 50 μg/ml soybean trypsin inhibitor] using a Dounce homogenizer The homogenate was stirred in a mechanical rotator for
30 min at 4°C and subsequently centrifuged at 10,000 x g for 10 min at 4°C. Supernatant was assayed for protein content using the Bio-Rad protein assay kit (Bio-Rad, hercules, CA). Aliquots of cell lysate containing 1 mg protein were incubatd overnight at 4°C with 1 μg polyclonal antibody to EGFR (Santa Cruz Biotechnology, Santa Cruz, CA). The immune complexes were precipitated with Sepharose bound protein-G, washed several times with kinase buffer (25 mM HEPES, pH 7.5, 5 mM mnCl2, 2.5 mM MgCl2, 0.5 mM, ditheothreitol, 0.5 mM Na3VO4, 10 mM p-nitrophenol phosphate, 5 mM β-glyverol phosphate). The immunoprecipitates were resuspending in 30 μl kinase reaction buffer [HEPES, pH 7.5, 10 mM MnCl2, 2.5 mM MgCl2, 0.1 M Nacl
150 mM Ncl, 0.5 mM ditheothreitol, 0.5 mM Na3VO4, 10 mM p-nitrophenol phosphate, 5 mM β-glyverol phosphate and 0.1 mM ATP] and assayed for tyrosine kinase activity by measuring ^incorporation from [γ-32P]ATP into acid-denatured enolase.

Claims

I claim:
1. A polynucleotide as shown in the ERRP nucleotide sequence.
2. A protein whose amino acid sequence is described in the amino acid sequence.
3. An ERRP fusion protein.
4. A colon cancer cell line stably transfected with ERRP.
5. The cell line of claim 4 wherein the cell line is human colon cancr cell line HCT-116.
6. An RNA probe of the polynucleotides shown in the ERRP nucleotide sequence.
7. A method for stably transfecting a cell line with an ERRP vector comprising the steps: the cDNA of the nucleotide sequence is subcloned into a
KS+ vector; the KS+ vector is digested with PUU II followed by ECOR I; the resulting fragment is inserted into ECO RI/ECOR V cloning sites of eukaryetic expression vector pc DNA 3.1(+); the resulting construct in them used to stably transfect a cell line.
8. The method of claim 7 wherein, the cell line is human.
9. The method of claim 8 wherein the cell line in colon cancer cell line HCT-116.
PCT/US2000/012884 1999-05-14 2000-05-12 Isolation and characterization of epidermal growth factor related protein WO2000069909A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU50032/00A AU5003200A (en) 1999-05-14 2000-05-12 Isolation and characterization of epidermal growth factor related protein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13420099P 1999-05-14 1999-05-14
US60/134,200 1999-05-14

Publications (2)

Publication Number Publication Date
WO2000069909A1 WO2000069909A1 (en) 2000-11-23
WO2000069909A9 true WO2000069909A9 (en) 2002-07-04

Family

ID=22462214

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/012884 WO2000069909A1 (en) 1999-05-14 2000-05-12 Isolation and characterization of epidermal growth factor related protein

Country Status (3)

Country Link
US (2) US6399743B1 (en)
AU (1) AU5003200A (en)
WO (1) WO2000069909A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US7625859B1 (en) * 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7396810B1 (en) * 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
EP1585966B8 (en) 2002-07-15 2012-03-07 F. Hoffmann-La Roche AG Treatment of cancer with the anti-ErbB2 antibody rhuMAb 2C4
US20050239088A1 (en) * 2003-05-16 2005-10-27 Shepard H M Intron fusion proteins, and methods of identifying and using same
EP1493445A1 (en) * 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of stress-induced ligand-dependent EGFR activation
US20060286102A1 (en) * 2004-05-14 2006-12-21 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
CN114053429A (en) 2004-06-01 2022-02-18 健泰科生物技术公司 Antibody-drug conjugates and methods
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
NZ553500A (en) 2004-09-23 2009-11-27 Genentech Inc Genentech Inc Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain
AU2005294347A1 (en) * 2004-10-05 2006-04-20 Oregon Health And Science University Compositions and methods for treating disease
US20090170769A1 (en) * 2005-05-13 2009-07-02 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
WO2011008768A1 (en) 2009-07-13 2011-01-20 Wayne State University Modified egfr ectodomain
KR20120123299A (en) 2009-12-04 2012-11-08 제넨테크, 인크. Multispecific antibodies, antibody analogs, compositions, and methods

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838216B1 (en) 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
CA1310924C (en) 1986-04-24 1992-12-01 Francis P. Mccormick Infective drug delivery system
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
JP3040121B2 (en) 1988-01-12 2000-05-08 ジェネンテク,インコーポレイテッド Methods of treating tumor cells by inhibiting growth factor receptor function
US5997859A (en) 1988-03-21 1999-12-07 Chiron Corporation Method for treating a metastatic carcinoma using a conditionally lethal gene
ATE174514T1 (en) 1989-01-23 1999-01-15 Chiron Corp RECOMBINANT CELLS FOR THERAPY OF INFECTIONS AND HYPERPRODELIVERY DISORDERS AND THEIR PRODUCTION
CA2055441C (en) 1989-05-19 2003-01-07 Robert M. Hudziak Her2 extracellular domain
EP0497922B1 (en) 1989-10-24 2002-01-30 Chiron Corporation Infective protein delivery system
US5362716A (en) 1989-12-27 1994-11-08 The United States Of America As Represented By The Department Of Health And Human Services Methods for stimulating hematopoietic progenitors using hepatocyte growth factor and lymphokines
US5459061A (en) * 1990-01-26 1995-10-17 W. Alton Jones Cell Science Center, Inc. Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor
US5578482A (en) 1990-05-25 1996-11-26 Georgetown University Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses
US5641484A (en) 1990-12-04 1997-06-24 Board Of Regents, The University Of Texas System Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen
DK0560932T3 (en) 1990-12-04 1997-02-17 Univ Texas
US5643567A (en) 1990-12-04 1997-07-01 Board Of Regents, The University Of Texas System Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen
US5344760A (en) * 1991-06-03 1994-09-06 Ciba Corning Diagnostics Corp. Method of cancer detection
WO1993010814A1 (en) 1991-11-29 1993-06-10 Viagene, Inc. Anti-cancer immunotherapeutic vector constructs
AU5355594A (en) 1992-10-09 1994-05-09 Oncor, Inc. Methods for the detection of chromosome structural abnormalities by (in situ) hybridization to fixed tissue
US5869445A (en) 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US5550214A (en) 1994-02-10 1996-08-27 Brigham And Women's Hospital Isolated antigenic oncogene peptide fragments and uses
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
WO1995030331A1 (en) 1994-05-05 1995-11-16 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
TW321649B (en) 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
US5807989A (en) 1994-12-23 1998-09-15 New York University Methods for treatment or diagnosis of diseases or disorders associated with an APB domain
US5721277A (en) 1995-04-21 1998-02-24 Sugen, Inc. Compounds and methods for inhibiting hyper-proliferative cell growth
WO1996033977A1 (en) 1995-04-27 1996-10-31 Zeneca Limited Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508537D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5773459A (en) 1995-06-07 1998-06-30 Sugen, Inc. Urea- and thiourea-type compounds
US5763470A (en) 1995-06-07 1998-06-09 Sugen Inc. Benzopyran compounds and methods for their use
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5710173A (en) 1995-06-07 1998-01-20 Sugen, Inc. Thienyl compounds for inhibition of cell proliferative disorders
WO1996040629A1 (en) 1995-06-07 1996-12-19 Sugen, Inc. Tyrphostin-like compounds for the treatment of cell proliferative disorders or cell differentiation disorders
US5650415A (en) 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
GB9603097D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
DE19608653A1 (en) 1996-03-06 1997-09-11 Thomae Gmbh Dr K Pyrimido [5,4-d] pyrimidines, medicaments containing these compounds, their use and processes for their preparation
US5998136A (en) 1996-08-19 1999-12-07 Arcaris, Inc. Selection systems and methods for identifying genes and gene products involved in cell proliferation
US6051593A (en) 1997-06-20 2000-04-18 Sugen, Inc. 3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine kinase inhibitors
US5972639A (en) 1997-07-24 1999-10-26 Irori Fluorescence-based assays for measuring cell proliferation

Also Published As

Publication number Publication date
US6582934B2 (en) 2003-06-24
WO2000069909A1 (en) 2000-11-23
AU5003200A (en) 2000-12-05
US20020045215A1 (en) 2002-04-18
US6399743B1 (en) 2002-06-04

Similar Documents

Publication Publication Date Title
Scott et al. A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells
Johnson et al. Expression and structure of the human NGF receptor
US6399743B1 (en) Isolation and characterization of a rat epidermal growth factor related protein
Johnson et al. Diverse forms of a receptor for acidic and basic fibroblast growth factors
Carlomagno et al. Molecular heterogeneity of RET loss of function in Hirschsprung's disease.
Stenzel et al. Identification of a novel murine receptor for corticotropin-releasing hormone expressed in the heart.
US7335357B2 (en) Antagonists of neuropilin receptor function and use thereof
Borrello et al. The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cγ
Fishburn et al. A novel short isoform of the D3 dopamine receptor generated by alternative splicing in the third cytoplasmic loop.
AU676502B2 (en) HER4 human receptor tyrosine kinase
Hugnot et al. Kv8. 1, a new neuronal potassium channel subunit with specific inhibitory properties towards Shab and Shaw channels.
Hawley et al. NGF induces the expression of the VGF gene through a cAMP response element
US20060035855A1 (en) Purified polypeptides having IL-13 receptor activity
US7557187B2 (en) Purified SR-p70 protein
Yu et al. Cloning of a novel EGFR-related peptide: a putative negative regulator of EGFR
Scata et al. FGF receptor availability regulates skeletal myogenesis
Moguilevsky et al. Stable Expression of Human H1‐histamine‐receptor cDNA in Chinese Hamster Ovary Cells: Pharmacological Characterisation of the Protein, Tissue Distribution of Messenger RNA and Chromosomal Localisation of the Gene
EP0856581B1 (en) Stably transfected cell lines expressing GABA-A receptors with the subunit combination alpha-3, beta-3 and gamma-2
Ichihara et al. Impaired interleukin‐3 (IL‐3) response of the A/J mouse is caused by a branch point deletion in the IL‐3 receptor alpha subunit gene.
Le Van Thai et al. Identification of a neuron-specific promoter of human aromatic L-amino acid decarboxylase gene
Cheng et al. Oligodendrocytes as glucocorticoids target cells: functional analysis of the glycerol phosphate dehydrogenase gene
Wen et al. Lipocortin V may function as a signaling protein for vascular endothelial growth factor receptor-2/Flk-1
Srinivasan et al. Intracellular expression of the truncated extracellular domain of c-erbB-3/HER3
Bedell et al. Multiple pathways for Steel regulation suggested by genomic and sequence analysis of the murine Steel gene
Lee et al. Intracellular retention of membrane-anchored v-sis protein abrogates autocrine signal transduction.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/12-12/12, DRAWINGS, REPLACED BY NEW PAGES 1/10-10/10; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP